WellCare Resolves SEC Probe
WellCare will pay a total civil penalty of $10 million, and $1 for disgorgement, in addition to post-judgment interest. The initial payment of $2.5 million will be paid
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.